A Phase 1/1b Study of Paclitaxel in Combination With BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients With Advanced Nonhaematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 04 Feb 2019
At a glance
- Drugs BOS 172722 (Primary) ; Paclitaxel
- Indications Breast cancer; Male breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Boston Pharmaceuticals
- 24 Jan 2019 Planned End Date changed from 1 Oct 2019 to 1 Dec 2020.
- 24 Jan 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Dec 2020.
- 07 Nov 2017 New trial record